about
MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcomeKinetics of IL-6 production defines T effector cell responsiveness to regulatory T cells in multiple sclerosisAdding Papillomacular Bundle Measurements to Standard Optical Coherence Tomography Does Not Increase Sensitivity to Detect Prior Optic Neuritis in Patients with Multiple Sclerosis.MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway.Herpes simplex virus encephalitis: chronic progressive cerebral MRI changes despite good clinical recovery and low viral load - an experimental mouse study.Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients.Experimental herpes simplex virus encephalitis: inhibition of the expression of inducible nitric oxide synthase in mouse brain tissue.Acyclovir treatment of experimentally induced herpes simplex virus encephalitis: monitoring the changes in immunologic NO synthase expression and viral load within brain tissue of SJL mice.Correction: Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis.Baló's concentric sclerosis is immunologically distinct from multiple sclerosis: results from retrospective analysis of almost 150 lumbar punctures.Myeloid dendritic cells exhibit defects in activation and function in patients with multiple sclerosis.Hypovitaminosis D upscales B-cell immunoreactivity in multiple sclerosis.Prevalence of newly generated naive regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis.MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature.Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis.In contrast to effector T cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death.In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients.Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar puncturesMolecular analysis of the CDR3 encoding region of the immunoglobulin heavy chain locus in cerebrospinal fluid cells as a diagnostic tool in lymphomatous meningitisIndependent HIV replication in paired CSF and blood viral isolates during antiretroviral therapyThymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosisRapid distinction of acute demyelinating disorders and central nervous system lymphoma by molecular analysis of cerebrospinal fluid cellsDiagnosis of cytomegalovirus encephalitis in patients with AIDS by quantitation of cytomegalovirus genomes in cells of cerebrospinal fluid[Value of polymerase chain reaction (PCR) for diagnosis of tuberculoid meningitis][Leptomeningeal dissemination of chronic lymphatic leukemia. Molecular genetic detection in cerebrospinal fluid]Mutations in the COL5A1 coding sequence are not common in patients with spontaneous cervical artery dissectionsSimilar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individualsSpecific recruitment of regulatory T cells into the CSF in lymphomatous and carcinomatous meningitisFingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosisPlasmacytosis is a common immune signature in patients with MMN and CIDP and responds to treatment with IVIgEfficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation
P50
Q30371412-8271AA95-0CDF-4DBE-B548-14587F31B5CEQ35025511-4E737997-76ED-4870-88D5-79F38D353F81Q36015674-4361F2BE-1005-4B86-9D0A-BEA857A920BEQ37374434-BDC3005A-F34E-4FB9-BAD5-2C47AD1D91F2Q39887068-90AEB34F-F9D9-4735-9936-6EA7F433EF59Q40933709-68E607B1-1FA2-49C5-BECE-E85B74CAA468Q41869890-585FF008-615A-4146-A794-F38660403C37Q43851042-A83D791A-CCAE-47D9-AF42-18F1CAFE51A7Q43983818-57277CCB-D054-481E-8B93-B149EB6F0801Q45791660-3A75DA84-D4BC-437A-8622-CE1F139924FAQ49204844-8B533286-3AF1-43E9-9CB6-DAAE74BD27DBQ50612510-AFD1D560-BD20-495A-A535-3F11AF6757C2Q50652297-BC3C8C23-FCFA-46E9-AFDF-8520B5309FB4Q51973817-AF64E0A9-8FC7-4B41-B1A5-E4AA41133FEAQ52648377-2099A48C-EABC-4B15-9D18-EDB4020C1E61Q53140129-88035E46-FF0A-4EB9-ADD4-58754760A258Q53654834-14FAED74-A217-4C0F-9E4D-CF1256CCF8AEQ53669552-8AF30145-7CCE-4AE4-B0A0-EEE7EC3412A4Q54225973-CAAF503D-70F1-41C8-8FED-14FBCC15078FQ64089583-1C423BBB-AE34-405E-A37F-80583B4860C2Q73425512-EA598479-0B63-44E4-A1A1-1388837F7F5FQ73426525-097C24BB-5810-46BF-B20B-56A1A3939B37Q73552896-3072CCAB-3DC2-4605-9945-78AA332E5B0FQ73705080-8EF62BEB-B6F6-4BE2-911F-D45967FADEB3Q74376387-DD600EA8-0BBB-4F07-A5FC-32612B6654BCQ74799044-F272A9BA-B2D0-4D1E-B5AA-3F739A0730DFQ77831758-7E83C7A6-D6BF-456E-AFD6-12709B63A79FQ78202774-E4CFB2D3-846D-4A23-8487-063DF7C3AE6FQ79339879-8437AA4F-79ED-46DC-8E86-6E9B38AEFF7CQ81515402-16A196B5-E3C0-43E2-8D40-563EBB8EDB3AQ86519809-6C0D9208-3566-433A-BC08-E658E68C7D1EQ86546788-868C719F-B98F-4CBB-917F-C421C8BAD311Q93185698-DE856DAB-BD35-4C1E-90C6-184621C76809
P50
description
researcher (ORCID 0000-0002-2314-7465)
@en
wetenschapper
@nl
name
Juergen Haas
@ast
Juergen Haas
@en
Juergen Haas
@nl
type
label
Juergen Haas
@ast
Juergen Haas
@en
Juergen Haas
@nl
prefLabel
Juergen Haas
@ast
Juergen Haas
@en
Juergen Haas
@nl
P106
P2798
P31
P496
0000-0002-2314-7465